Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

Research grant holder first to be graded at UFS in NRF’s Thuthuka Programme
2007-11-17

 

In the picture, from the left are: Ms Gudrun Schirge (National Research Foundation), Mr Nico Benson (Directorate Research Development at the UFS), Prof Heidi Hudson (Department of Political Science at the UFS) and Dr Annelize Venter (Co-ordinator of the Thuthuka Programme at the UFS)
Photo: Mangaliso Radebe

 

Research grant holder first to be graded at UFS in NRF’s Thuthuka Programme

Prof. Heidi Hudson, Departmental Chairperson at the University of the Free State's (UFS) Department of Political Science, recently received a C1 grading from the National Research Foundation (NRF).

With this grading she became the first researcher and grant holder in the Thuthuka Programme for young researchers at the UFS to be graded by the NRF.

“The Thuthuka Programme is a capacity building initiative from the NRF which prepares young researchers for grading and provides them with a good grounding for research,” said Dr Annelize Venter, researcher at the UFS Research Development Directorate and co-ordinator of the Thuthuka Programme.

According to Dr Venter, the UFS currently has 44 researchers who receive funding from the Thuthuka Programme for their postgraduate studies. The results of possible entrants to the programme in 2008 are awaited.

”The UFS also received ten researchers additional to the current 69 who have a valid evaluation status. The results of an additional 11 applications are also awaited. Some of these are first applications,” said Dr Venter.

Over and above the grant holders in the Thuthuka Programme, any researcher can apply to be evaluated by the NRF’s Evaluation Centre. The evaluation status of a researcher serves as the norm determinator and the quality of research at a university is measured according to this.

Ms Gudrun Schirge from the NRF presented a workshop today at the UFS to researchers who wanted to apply for grading and evaluation.
Researchers who wished to apply for the re-evaluation of their current evaluation status also attended the workshop.

Ms Schirge was one of the founders of the evaluation system and has been a manager at the Evaluation Centre for the past 20 years. She will be retiring this year and will be involved with the centre on a part-time basis.

Media Release
Issued by: Lacea Loader
Assistant Director: Media Liaison
Tel: 051 401 2584
Cell: 083 645 2454
E-mail: loaderl.stg@ufs.ac.za  
16 November 2007
 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept